Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Two Schedules of Zoledronic Acid in Treating Patients With Breast Cancer That Has Spread to the Bone

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed primary breast cancer~  * Advanced disease~* Radiographic confirmation of bone metastases (≥ 1 bone scan lesion must be confirmed as metastatic by plain radiographs or CT scan/MRI)~  * Must have received zoledronic acid to treat metastatic bone disease (i.e., ≥ 4 or 5 zoledronic acid treatments prior to study entry for patients receiving 4- or 3-weekly infusions, respectively) for ≥ 4 months prior to study entry~ * Any bisphosphonate to treat metastatic bone disease allowed provided it was not given for more than 12 months prior to study entry~* No metabolic bone disease (e.g., Paget's disease of bone)~  * Osteoporosis allowed~* No brain metastases~* Hormone receptor status not specified~PATIENT CHARACTERISTICS:~* Male or female~* Menopausal status not specified~* WHO or ECOG performance status 0-2~* Life expectancy ≥ 6 months~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* AST and ALT ≤ 3 times upper limit of normal (ULN)~* Bilirubin ≤ 1.5 times ULN~* Creatinine clearance ≥ 30 mL/min~* No poor venous access~* No concurrent active dental problems, including infection of the teeth or jawbone (maxilla or mandibular)~* No prior or current diagnosis of osteonecrosis of the jaw~* No other cancer within the past 5 years except nonmelanomatous skin cancer, carcinoma in situ of the uterine cervix, or superficial bladder cancer treated with curative intent~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* No other prior bisphosphonate treatment within the past 3 weeks~* No treatment with systemic bone-seeking radioisotopes (e.g., strontium chloride Sr 89, samarium Sm 153 lexidronam pentasodium) within the past 3 months~* No wide-field (hemibody) radiotherapy within the past 3 months~  * Recent standard-field, localized radiotherapy allowed~* No dental or jaw surgery (e.g., extractions, implants) within the past 4 weeks~* No other concurrent bisphosphonates~* No concurrent medication with drugs known to affect bone metabolism (e.g., calcitonin or high-dose systemic corticosteroids \[\> 10 mg prednisolone/day or equivalent\])~  * Systemic or oral corticosteroids allowed for clearly indicated conditions (e.g., chemotherapy-induced emesis, brain metastases, compression syndromes)~* Concurrent chemotherapy, biological therapy, or endocrine therapy allowed

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).